ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition
Authors
Keywords
-
Journal
BLOOD
Volume 139, Issue 2, Pages 256-280
Publisher
American Society of Hematology
Online
2021-11-03
DOI
10.1182/blood.2021013338
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Single‐agent cladribine as an effective front‐line therapy for adults with Langerhans cell histiocytosis
- (2021) Gaurav Goyal et al. AMERICAN JOURNAL OF HEMATOLOGY
- Histiocytosis
- (2021) Jean-François Emile et al. LANCET
- Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma
- (2021) Lucas R. Massoth et al. ONCOLOGIST
- Localized ALK-positive histiocytosis in a Chinese woman: report of a case in the lung with a novel EML4-ALK rearrangement
- (2021) Yanhua Bai et al. VIRCHOWS ARCHIV
- Distinct Clinicopathologic Features and Possible Pathogenesis of Localized ALK-positive Histiocytosis of the Breast
- (2021) Tomo Osako et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- ALK ‐rearranged histiocytosis: Report of two cases with involvement of the central nervous system
- (2021) Sabrina Rossi et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Notable therapeutic response in a patient with systemic juvenile xanthogranuloma with KIF5B‐ALK fusion
- (2021) Minako Sugiyama et al. PEDIATRIC BLOOD & CANCER
- Neurologic and oncologic features of Erdheim–Chester disease: a 30-patient series
- (2020) Ankush Bhatia et al. NEURO-ONCOLOGY
- Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era
- (2020) Gaurav Goyal et al. BLOOD
- Long‐term outcomes of children with extracutaneous juvenile xanthogranulomas in Japan
- (2020) Miho Maeda et al. PEDIATRIC BLOOD & CANCER
- ALK-Positive Histiocytosis with Peripheral Blood Histiocytes: A Case Report
- (2020) Fiona Swain et al. ACTA HAEMATOLOGICA
- ALK-positive Histiocytosis of the Breast
- (2020) Jumpei Kashima et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Systemic Juvenile Xanthogranuloma has a Higher Frequency of ALK Translocations than BRAFV600E Mutations
- (2020) Jiaosheng Xu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- ALK-positive histiocytosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: a multitarget response under ibrutinib
- (2020) Charlotte Syrykh et al. VIRCHOWS ARCHIV
- Local ALK-Positive Histiocytosis With Unusual Morphology and Novel TRIM33-ALK Gene Fusion
- (2020) Tien Anh N. Tran et al. INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY
- Disseminated ALK-positive histiocytosis with KIF5B-ALK fusion in an adult
- (2020) Lianqun Qiu et al. LEUKEMIA & LYMPHOMA
- Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma
- (2019) Vignesh Shanmugam et al. MODERN PATHOLOGY
- Efficacy of MEK inhibition in patients with histiocytic neoplasms
- (2019) Eli L. Diamond et al. NATURE
- ALK-positive histiocytosis with KIF5B-ALK fusion in the central nervous system
- (2019) Calixto-Hope G. Lucas et al. ACTA NEUROPATHOLOGICA
- ALK Expression in Angiomatoid Fibrous Histiocytoma
- (2019) Peter Van Zwam et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver alteration detected by DNA sequencing and low tumor mutation burden
- (2019) Ryma Benayed et al. CLINICAL CANCER RESEARCH
- Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity
- (2019) Ibiayi Dagogo-Jack et al. CLINICAL CANCER RESEARCH
- ALK-positive histiocytosis with KIF5B-ALK fusion in an adult female
- (2019) Gaurav K. Gupta et al. HAEMATOLOGICA
- One-fits-all pretreatment protocol facilitating Fluorescence In Situ Hybridization on formalin-fixed paraffin-embedded, fresh frozen and cytological slides
- (2019) Shivanand O. Richardson et al. Molecular Cytogenetics
- A Phase 1 and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients With Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors
- (2019) Mark W. Kieran et al. CLINICAL CANCER RESEARCH
- Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups
- (2019) Caoimhe Egan et al. HAEMATOLOGICA
- Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study
- (2019) Jean Donadieu et al. JOURNAL OF CLINICAL ONCOLOGY
- Atypical juvenile histiocytosis with novel KIF5B-ALK gene fusion mimicking subglottic hemangioma
- (2019) Nikolaus E. Wolter et al. INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY
- Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms
- (2019) Benjamin H. Durham et al. NATURE MEDICINE
- BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease
- (2019) J. Picarsic et al. Acta Neuropathologica Communications
- The coming of age of Langerhans cell histiocytosis
- (2019) Carl E. Allen et al. NATURE IMMUNOLOGY
- Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort
- (2018) Fleur Cohen-Aubart et al. AMERICAN JOURNAL OF HEMATOLOGY
- ALK Expression in Angiomatoid Fibrous Histiocytoma
- (2018) Alison L. Cheah et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Single-agent dabrafenib for BRAF V600E -mutated histiocytosis
- (2018) Ankush Bhatia et al. HAEMATOLOGICA
- Epithelioid fibrous histiocytoma: molecular characterization of ALK fusion partners in 23 cases
- (2018) Brendan C Dickson et al. MODERN PATHOLOGY
- Single-agent dabrafenib for BRAF V600E -mutated histiocytosis
- (2018) Ankush Bhatia et al. HAEMATOLOGICA
- Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis
- (2018) Eli L. Diamond et al. JAMA Oncology
- Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study
- (2018) Sébastien Héritier et al. BRITISH JOURNAL OF HAEMATOLOGY
- ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion
- (2018) Kenneth Tou En Chang et al. MODERN PATHOLOGY
- Histiocytoses: emerging neoplasia behind inflammation
- (2017) Julien Haroche et al. LANCET ONCOLOGY
- Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai–Dorfman disease
- (2017) Sofia Garces et al. MODERN PATHOLOGY
- ALKFusions in a Wide Variety of Tumor Types Respond to Anti‐ALK Targeted Therapy
- (2017) Jeffrey S. Ross et al. ONCOLOGIST
- Expanding the Phenotype of ALK-positive Histiocytosis: A Report of 2 Cases
- (2017) Huiya Huang et al. PEDIATRIC AND DEVELOPMENTAL PATHOLOGY
- Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases
- (2017) Fabio Facchetti et al. VIRCHOWS ARCHIV
- Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease
- (2017) Gaurav Goyal et al. JAMA Oncology
- The role of the ALK receptor in cancer biology
- (2016) B. Hallberg et al. ANNALS OF ONCOLOGY
- Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
- (2016) J.-F. Emile et al. BLOOD
- Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis
- (2016) Rikhia Chakraborty et al. BLOOD
- Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease
- (2016) Fleur Cohen Aubart et al. BRITISH JOURNAL OF HAEMATOLOGY
- Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age
- (2016) Charlotte Rigaud et al. BRITISH JOURNAL OF HAEMATOLOGY
- MAP2K1andMAP3K1mutations in langerhans cell histiocytosis
- (2015) David S. Nelson et al. GENES CHROMOSOMES & CANCER
- I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib
- (2015) Sai-Hong Ignatius Ou et al. LUNG CANCER
- ALK rearrangement and overexpression in epithelioid fibrous histiocytoma
- (2015) Leona A Doyle et al. MODERN PATHOLOGY
- Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
- (2015) E. L. Diamond et al. Cancer Discovery
- Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease
- (2014) J.-F. Emile et al. BLOOD
- Somatic activating ARAF mutations in Langerhans cell histiocytosis
- (2014) D. S. Nelson et al. BLOOD
- High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis
- (2014) N. A. Brown et al. BLOOD
- Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis
- (2014) R. Chakraborty et al. BLOOD
- Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
- (2014) C. M. Lovly et al. Cancer Discovery
- Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation
- (2012) J. Haroche et al. BLOOD
- High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses
- (2012) J. Haroche et al. BLOOD
- Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years
- (2012) Riccardo Haupt et al. PEDIATRIC BLOOD & CANCER
- Recurrent BRAF mutations in Langerhans cell histiocytosis
- (2010) G. Badalian-Very et al. BLOOD
- ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy
- (2008) J. K. C. Chan et al. BLOOD
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started